首页> 美国卫生研究院文献>Thorax >Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.
【2h】

Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.

机译:解释阻塞性气道疾病患者的支气管扩张药反应。荷兰慢性非特异性肺疾病(CNSLD)研究组。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: There is no agreement on how a bronchodilator response should be expressed. Ideally, the index used should be able to distinguish asthma from chronic obstructive lung disease and be independent of initial FEV1. METHODS: Two hundred and seventy four adults (aged 18-60 years) outpatients with obstructive airways disease were studied. Patients were divided into syndrome groups on the basis of a standardised history: asthma (n = 99), asthmatic bronchitis (n = 88), and chronic obstructive lung disease (n = 51); 36 subjects could not be attributed to any subgroup. FEV1 was measured before and 20 minutes after inhalation of 1000 micrograms terbutaline. Different expressions of bronchodilator response (delta FEV1) were compared with respect to their dependence on initial FEV1 and their efficacy in separating subjects with asthma from those with chronic obstructive lung disease. delta FEV1 was expressed as a percentage of initial FEV1 (delta FEV1%init), absolute value (delta FEV1[1]), percentage of predicted FEV1 (delta FEV1%pred), standardised residual (delta SR-FEV1), and percentage of maximal possible increase (delta FEV1%[pred-init]). RESULTS: delta FEV1%init was more dependent on initial FEV1 (p = -0.405) than delta FEV1[1] (r = -0.145), delta FEV1%pred (r = -0.166), and delta SR-FEV1 (r = -0.127). delta FEV1%[pred-init] reached infinity when initial FEV1 approached predicted levels. delta FEV1%pred had a higher likelihood ratio (1.71) for separating patients with asthma from those with chronic obstructive lung disease than other expressions of bronchodilator response. Asthmatic patients had larger mean bronchodilator responses than patients in other subgroups; this difference was largest for delta SR-FEV1 (F = 9.19) and delta FEV1%pred (F = 9.03); it was much smaller for delta FEV1%init (F = 5.89). Despite significant differences in mean response, there was a large overlap of individual responses between diagnostic subgroups. The bronchodilator response was continuously and unimodally distributed for all expressions. CONCLUSIONS: delta FEV1%pred appears to be the most useful method of expressing bronchodilator response, both for clinical and for research purposes. Reversibility of airways obstruction in response to a bronchodilator is a continuous variable and not a dichotomous triat. Any cut off level of a "positive" bronchodilator response is therefore arbitrary.
机译:背景:关于如何表达支气管扩张药反应尚无共识。理想情况下,使用的指数应能够区分哮喘与慢性阻塞性肺疾病,并且与初始FEV1无关。方法:对274名成人(年龄在18-60岁)患有阻塞性气道疾病的门诊患者进行了研究。根据标准化病史将患者分为综合征组:哮喘(n = 99),哮喘性支气管炎(n = 88)和慢性阻塞性肺疾病(n = 51); 36个主题不能归因于任何子组。在吸入1000微克特布他林之前和之后20分钟测量FEV1。比较了支气管扩张剂反应的不同表达(δFEV1),它们对初始FEV1的依赖性及其在将哮喘患者与慢性阻塞性肺疾病患者分离中的功效。增量FEV1表示为初始FEV1的百分比(增量FEV1%init),绝对值(增量FEV1 [1]),预测FEV1的百分比(增量FEV1%pred),标准化残差(增量SR-FEV1)和最大可能的增量(增量FEV1%[pred-init])。结果:增量FEV1%init比增量FEV1 [1](r = -0.145),增量FEV1%pred(r = -0.166)和增量SR-FEV1(r = -0.127)。当初始FEV1达到预测水平时,ΔFEV1%[pred-init]达到无穷大。与其他支气管扩张剂反应表达相比,delta FEV1%pred将哮喘患者与慢性阻塞性肺疾病患者分离的可能性更高(1.71)。哮喘患者比其他亚组的患者平均支气管扩张药反应更大。对于差异SR-FEV1(F = 9.19)和差异FEV1%pred(F = 9.03),差异最大。对于增量FEV1%init(F = 5.89),它要小得多。尽管平均反应存在显着差异,但诊断亚组之间的个体反应仍存在很大的重叠。支气管扩张剂反应对于所有表达均连续且单峰分布。结论:对于临床和研究目的,δFEV1%pred似乎是表达支气管扩张剂反应的最有用的方法。响应支气管扩张剂时气道阻塞的可逆性是连续变量,而不是二分法。因此,“阳性”支气管扩张药反应的任何截止水平都是任意的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号